Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Overview
Learn About Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Friedemann Paul practices in Goyang, Republic of Korea. Paul is rated as an Elite expert by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Their top areas of expertise are Multiple Sclerosis (MS), Transverse Myelitis, Optic Neuritis, and Neuromyelitis Optica.
Mayo Clinic
Sean Pittock is a Neurologist in Rochester, Minnesota. Dr. Pittock is rated as an Elite provider by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. His top areas of expertise are Transverse Myelitis, Optic Neuritis, Neuromyelitis Optica, and Encephalitis. Dr. Pittock is currently accepting new patients.
Mayo Clinic
Jan-mendelt Tillema is a Neurologist in Rochester, Minnesota. Dr. Tillema is rated as an Elite provider by MediFind in the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. His top areas of expertise are Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Multiple Sclerosis (MS), Encephalitis, and Optic Neuritis. Dr. Tillema is currently accepting new patients.
Summary: The RECLAIM study aims to gather a centralized and harmonized dataset, enabling the secondary use of data for building AI-based models that will support diagnosis and prognosis of individual Multiple Sclerosis patient's disease course and treatment response in a real-world setting. Additionally, the data will be used to generate further insights on Multiple Sclerosis progression as well as to deve...
Summary: The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).